Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:744-750
Published online before print January 26, 2006, doi: 10.1161/01.ATV.0000205591.88522.d4
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/4/744    most recent
01.ATV.0000205591.88522.d4v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, T.
Right arrow Articles by Chemtob, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, T.
Right arrow Articles by Chemtob, S.
Related Collections
Right arrow Angiogenesis
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:744.)
© 2006 American Heart Association, Inc.


Vascular Biology

Proangiogenic Effects of Protease-Activated Receptor 2 Are Tumor Necrosis Factor-{alpha} and Consecutively Tie2 Dependent

Tang Zhu; Florian Sennlaub; Martin Hervé Beauchamp; Li Fan; Jean Sebastian Joyal; Daniella Checchin; Satra Nim; Pierre Lachapelle; Mirna Sirinyan; Xin Hou; Michela Bossolasco; Georges-Etienne Rivard; Nikolaus Heveker; Sylvain Chemtob

From the Departments of Pediatrics, Ophthalmology, Pharmacology (T.Z., F.S., M.H.B., D.C., S.N., M.S., X.H., M.B., S.C.), Hematology (L.F., G.E.R.), and Biochemistry (N.H.), Research Center of Hôpital Ste-Justine, Montréal, Quebec, Canada; and Departments of Ophthalmology, McGill University (P.L.), Montréal, Quebec, Canada.

Correspondence to Sylvain Chemtob, MD, PhD, Hôpital Ste-Justine, Research Center, 3175 Côte Ste-Catherine, Montréal, Québec, H3T 1C5, Canada. E-mail sylvain.chemtob{at}umontreal.ca

Objective— Angiogenesis is essential physiologically in growth and pathologically in tumor development, chronic inflammatory disorders, and proliferative retinopathies. Activation of protease-activated receptor 2 (PAR2) leads to a proangiogenic response, but its mechanisms have yet to be specifically described. Here, we investigated the mode of action of PAR2 in retinal angiogenesis.

Methods and Results— PAR2-activating peptide, SLIGRL, increased retinal angiogenesis associated with an induction of vascular endothelial growth factor and angiopoetin-2 and most notably tie2 in the retina in vivo as well as in cultured neuroretinal endothelial cells. SLIGRL also induced release of the proinflammatory and angiogenic mediator tumor necrosis factor-{alpha} (TNF-{alpha}) via the MEK/extracellular signal-regulated kinase (ERK) (MEK/ERK) pathway in these endothelial cells. TNF-{alpha}, in turn, elicited tie2 expression by activating the MEK/ERK pathway. PAR2-evoked tie2 expression, endothelium proliferation (in vitro), and retinal neovascularization (in vivo) were abrogated by selective TNF-{alpha} blockers (neutralizing antibody infliximab and soluble TNF-{alpha} receptor-Fc fusion protein etanercept) as well as the MEK inhibitor PD98059.

Conclusion— The proangiogenic properties of PAR2 are intertwined with its proinflammatory effects, such that in retinal vasculature, they depend on TNF-{alpha} and subsequent induction of tie2 via the MEK/ERK pathway.

This article investigated PAR2 activation in retinal angiogenesis. TNF-{alpha} inhibitors (infliximab and etanercept) and the MEK inhibitor PD98059 prevented tie2 upregulation, endothelium proliferation, and retinal neovascularization induced by PAR2 activation. The PAR2 proangiogenic properties are involved in its proinflammatory effects and subsequent induction of tie2 via the MEK/ERK pathway.


Key Words: protease-activated receptor 2 • angiogenesis • TNF-{alpha} • tie2 receptor • signaling transduction




This article has been cited by other articles:


Home page
Cancer Res.Home page
B. Li, A. Vincent, J. Cates, D. M. Brantley-Sieders, D. B. Polk, and P. P. Young
Low Levels of Tumor Necrosis Factor {alpha} Increase Tumor Growth by Inducing an Endothelial Phenotype of Monocytes Recruited to the Tumor Site
Cancer Res., January 1, 2009; 69(1): 338 - 348.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. H. Versteeg, F. Schaffner, M. Kerver, L. G. Ellies, P. Andrade-Gordon, B. M. Mueller, and W. Ruf
Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T Mice
Cancer Res., September 1, 2008; 68(17): 7219 - 7227.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Voskas, Y. Babichev, L. S. Ling, J. Alami, Y. Shaked, R. S. Kerbel, B. Ciruna, and D. J. Dumont
An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice
J. Leukoc. Biol., July 1, 2008; 84(1): 59 - 67.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Uusitalo-Jarvinen, T. Kurokawa, B. M. Mueller, P. Andrade-Gordon, M. Friedlander, and W. Ruf
Role of Protease Activated Receptor 1 and 2 Signaling in Hypoxia-Induced Angiogenesis
Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1456 - 1462.
[Abstract] [Full Text] [PDF]